Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Selumetinib plus dexamethasone in R/R ALL: a Phase I/II trial

Britta Vormoor • 10 Dec 2023
ASH 2023
Acute Lymphoblastic Leukemia Leukemia Dexamethasone Selumetinib

Britta Vormoor, MD, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, discusses a Phase I/II trial (NCT03705507) investigating selumetinib, a MEK1/2 inhibitor, combined with dexamethasone in the treatment of relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Despite initial safety concerns, successfully addressed through dose adjustments, 44% of participants achieved complete remission, underscoring the potential promise of this combination in the treatment of ALL. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Britta Vormoor

0:42
Challenges in treating patients with RAS-pathway activating mutations in ALL
Britta Vormoor • 10 Dec 2023
0:48
The issue of short-lived treatment responses in heavily pretreated patients with ALL
Britta Vormoor • 10 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals